Diabetes drug may be game changer
By Philip Joens / Friday, November 27th, 2015 / Central Coast Health Watch, Latest news, Top Stories / Comments Off on Diabetes drug may be game changer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen asks FDA to approve biosimilar drug
By Staff Report / Wednesday, November 25th, 2015 / Central Coast Health Watch, Latest news, Top Stories / Comments Off on Amgen asks FDA to approve biosimilar drug
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Read More →Sientra collapse doomed execs
By Philip Joens / Friday, November 20th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Sientra collapse doomed execs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Goleta breast implant maker Sientra shakes up C-Suite
By Philip Joens / Thursday, November 12th, 2015 / Central Coast Health Watch, Latest news, South Coast, Top Stories, Tri-County Public Companies / Comments Off on Goleta breast implant maker Sientra shakes up C-Suite
The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →
Read More →FDA to review Amgen’s new kidney disease dug
By Staff Report / Friday, November 6th, 2015 / Central Coast Health Watch, East Ventura County, Latest news / Comments Off on FDA to review Amgen’s new kidney disease dug
Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →
Read More →Goleta’s Sientra reassures investors, surgeons
By Philip Joens / Friday, November 6th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Goleta’s Sientra reassures investors, surgeons
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sientra sends letter to surgeons about breast implant production
By Philip Joens / Friday, October 30th, 2015 / Latest news, Top Stories, Tri-County Public Companies / Comments Off on Sientra sends letter to surgeons about breast implant production
Sientra CEO Hani Zeini issued a letter to plastic surgeons Oct. 30 outlining what the Goleta-based breast implant manufacturer needs to do to restart production at its plant in Brazil. Zeini also implied in the letter that the Food and Drug Administration is going to make a decision regarding Sientra products, which is something Read More →
Read More →Popular articles
- None Found
Sponsored content:
SHIPS SLOW TO PROTECT WHALES, BLUE SKIES
-
Sign up for email news
Get the Business Times in your inbox. Sign up for breaking news alerts, our weekly briefing, and more.Sign upFor Email Marketing you can trust.2015-2016 Giving Guide
Check out our 2015 Giving Guide special issue